Immunohistochemistry no longer only names a tumour — increasingly, it chooses the drug. A membrane score gates an antibody–drug conjugate; a percentage of stained nuclei opens or closes a line of therapy; a pattern of nuclear loss unlocks immunotherapy across the body.
Yet the threshold that decides treatment is not a fact about the tumour. It is a decision rule tied to a particular trial, a particular drug, and a particular assay. For every predictive marker, this pan-tumour guide sets out what to score, where the cutoff came from, how reproducibly it can be read, and how to report it in language the oncologist can act on.
Markers covered: PD-L1 · HER2 and HER2-low/ultralow · MMR/MSI · ER, PR and Ki-67 · Trop-2 · Nectin-4 · FRα · Claudin 18.2 · HER3 · B7-H3 · quantitative and AI-assisted scoring.
Inside this edition: fifteen focused chapters across four parts; the trial-validated cutoff behind every marker; reproducibility and the faint-end problem, marker by marker; pitfalls at the bench, controls, and external quality assurance; assay, clone and platform specifics throughout; and synoptic reporting templates.
Written for practising pathologists, trainees, and tumour-board participants.
Expression is not eligibility.
Le informazioni nella sezione "Riassunto" possono far riferimento a edizioni diverse di questo titolo.
Da: Majestic Books, Hounslow, Regno Unito
Condizione: New. pp. 600. Codice articolo 7557530
Quantità: 4 disponibili
Da: Books Puddle, Woodside, NY, U.S.A.
Condizione: New. pp. 600 Index. Codice articolo 26323141
Quantità: 4 disponibili
Da: Biblios, Frankfurt am main, HESSE, Germania
Condizione: New. pp. 600. Codice articolo 18323151
Quantità: 4 disponibili
Da: California Books, Miami, FL, U.S.A.
Condizione: New. Codice articolo I-9788190322805
Quantità: Più di 20 disponibili
Da: Grand Eagle Retail, Bensenville, IL, U.S.A.
Paperback. Condizione: new. Paperback. Immunohistochemistry no longer only names a tumour - increasingly, it chooses the drug. A membrane score gates an antibody-drug conjugate; a percentage of stained nuclei opens or closes a line of therapy; a pattern of nuclear loss unlocks immunotherapy across the body.Yet the threshold that decides treatment is not a fact about the tumour. It is a decision rule tied to a particular trial, a particular drug, and a particular assay. For every predictive marker, this pan-tumour guide sets out what to score, where the cutoff came from, how reproducibly it can be read, and how to report it in language the oncologist can act on.Markers covered: PD-L1 - HER2 and HER2-low/ultralow - MMR/MSI - ER, PR and Ki-67 - Trop-2 - Nectin-4 - FRa - Claudin 18.2 - HER3 - B7-H3 - quantitative and AI-assisted scoring.Inside this edition: fifteen focused chapters across four parts; the trial-validated cutoff behind every marker; reproducibility and the faint-end problem, marker by marker; pitfalls at the bench, controls, and external quality assurance; assay, clone and platform specifics throughout; and synoptic reporting templates.Written for practising pathologists, trainees, and tumour-board participants.Expression is not eligibility. This item is printed on demand. Shipping may be from multiple locations in the US or from the UK, depending on stock availability. Codice articolo 9788190322805
Quantità: 1 disponibili
Da: PBShop.store US, Wood Dale, IL, U.S.A.
PAP. Condizione: New. New Book. Shipped from UK. Established seller since 2000. Codice articolo L2-9788190322805
Quantità: Più di 20 disponibili
Da: PBShop.store UK, Fairford, GLOS, Regno Unito
PAP. Condizione: New. New Book. Shipped from UK. Established seller since 2000. Codice articolo L2-9788190322805
Quantità: Più di 20 disponibili
Da: CitiRetail, Stevenage, Regno Unito
Paperback. Condizione: new. Paperback. Immunohistochemistry no longer only names a tumour - increasingly, it chooses the drug. A membrane score gates an antibody-drug conjugate; a percentage of stained nuclei opens or closes a line of therapy; a pattern of nuclear loss unlocks immunotherapy across the body.Yet the threshold that decides treatment is not a fact about the tumour. It is a decision rule tied to a particular trial, a particular drug, and a particular assay. For every predictive marker, this pan-tumour guide sets out what to score, where the cutoff came from, how reproducibly it can be read, and how to report it in language the oncologist can act on.Markers covered: PD-L1 - HER2 and HER2-low/ultralow - MMR/MSI - ER, PR and Ki-67 - Trop-2 - Nectin-4 - FRa - Claudin 18.2 - HER3 - B7-H3 - quantitative and AI-assisted scoring.Inside this edition: fifteen focused chapters across four parts; the trial-validated cutoff behind every marker; reproducibility and the faint-end problem, marker by marker; pitfalls at the bench, controls, and external quality assurance; assay, clone and platform specifics throughout; and synoptic reporting templates.Written for practising pathologists, trainees, and tumour-board participants.Expression is not eligibility. This item is printed on demand. Shipping may be from our UK warehouse or from our Australian or US warehouses, depending on stock availability. Codice articolo 9788190322805
Quantità: 1 disponibili